J&J Consumer Unit Underperforms In Q3 As Recall Aftereffects Linger
This article was originally published in The Tan Sheet
Executive Summary
Johnson & Johnson's consumer business missed revised analyst estimates and dragged down overall sales in the third quarter of what can only be called a lost year for the unit
You may also be interested in...
Chattem To Revive Rolaids Line Bought From J&J
Chattem snaps up Rolaids from Johnson & Johnson subsidiary McNeil, which never restocked the iconic heartburn relief brand after recalling and suspending production in 2010. Sanofi touts Rolaids as “an enduring brand with a deep heritage.”
Chattem To Revive Rolaids Line Bought From J&J
Chattem snaps up Rolaids from Johnson & Johnson subsidiary McNeil, which never restocked the iconic heartburn relief brand after recalling and suspending production in 2010. Sanofi touts Rolaids as “an enduring brand with a deep heritage.”
McNeil OTC Recalls Slice $900M From J&J's 2010 Sales
Recalled OTC drugs took a $900 million bite out of Johnson & Johnson's fiscal 2010 sales, including $300 million in the fourth quarter, contributing to what the company and analysts labeled disappointing earnings.